AHA 2011 Conference Review - reviewed by Professor John French

In this review:

Low-dose rivaroxaban beneficial in ACS
Vorapaxar: excess bleeding risk in ACS
Co-payment elimination for essential post-MI drugs
No benefit of IC over IV abciximab
Abciximab/heparin versus bivalirudin in NSTEMI
BMCs: no benefit in post-MI LV dysfunction

Please login below to download this issue (PDF)